Dose-dependency in pleiotropic effects of atorvastatin

International Journal of Angiology

Volumn 16, Issue 3, 2007, Pages 89-91

  Fujita, Masatoshi ^a   Morimoto, Tatsuya ^a   Ikemoto, Masaki ^a   Takeda, Mayu ^a   Ikai, Akiko ^a   Miwa, Kunihisa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Fibrinolysis; Inflammation; Oxidative stress; Statins

Indexed keywords

EID: 80053002718     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1278256     Document Type: Article

References (16)

1. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-67.
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
3. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:64-70. (Pubitemid 32606333)
4. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285-8. (Pubitemid 34847957)
5. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9. (Pubitemid 34219772)
6. Topol EJ. Intensive statin therapy-a sea change in cardiovascular prevention. N Engl J Med 2004;350:1562-4. (Pubitemid 38477782)
7. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91. (Pubitemid 23165620)
8. Packard CJ. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5. (Pubitemid 28191298)
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
10. McWhorter VC, Ford LC, Butch AW. Analytical performance of the Synchron LX20 Pro, BN trade mark II and IMMAGE high sensitivity C-creative protein assays and concordance in cardiovascular risk stratification. Clin Chim Acta 2004;347:71-9. (Pubitemid 39099607)
11. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7. (Pubitemid 34225391)
12. Yin B, Whyatt RM, Perera F P, Randall MC, Cooper TB, Santella RM. Determination of 8-hydroxydeoxyguanosine by an immunoaffinity chromatography-monoclonal antibody-based ELISA. Free Radic Biol Med 1992;18:1023-32.
13. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003;92:10i-18i. (Pubitemid 36831110)
14. Tekin A, Tekin G, Güzelsoy D, et al. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am J Cardiol 2004;94:206-9. (Pubitemid 38902873)
15. Demir M, Acarturk E, Saamaz I, Cayli M, Kikinc Y. Effects of atorvastatin on lipid profile and coagulation parameters. Curr Ther Res Clin Exp 2001;62:691-8. (Pubitemid 33097453)
16. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001;154:87-96. (Pubitemid 32008567)